Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Ostyn, Pauline ^a   Machhour, Raja El ^a   Begard, Severine ^a   Kotecki, Nuria ^a   Vandomme, Jerome ^a,b   Flamenco, Pilar ^a   Segard, Pascaline ^a,b   Masselot, Bernadette ^a,b   Formstecher, Pierre ^a,b,c   Touil, Yasmine ^a,d   Polakowska, Renata ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c Service de Pathologie Professionnelle et Environnement   (France)

^d SIRIC OncoLille   (France)

Author keywords

Cancer stem cells; Label retaining cell; Melanoma; Quiescence; TNF

Indexed keywords

ABC TRANSPORTER B5; CD271 ANTIGEN; CELL ANTIGEN; MELANOMA ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL POPULATION; CELL RENEWAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELANOMA; PHENOTYPE; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; ADULT; CELL CULTURE; FEMALE; FIBROBLAST; KERATINOCYTE; METABOLISM; SKIN; SKIN TUMOR; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; KERATINOCYTES; MELANOMA; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SKIN; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908159714     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0052-z     Document Type: Article

References (78)

1. Ossowski L, Aguirre-Ghiso JA: Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010, 23:41-56.
2. Strauss DC, Thomas JM: Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010, 11:790-796.
3. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
4. Chomel J-C, Turhan AG: Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011, 2:713-727.
5. Alison MR, Lin W-R, Lim SML, Nicholson LJ: Cancer stem cells: in the line of fire. Cancer Treat Rev 2012, 38:589-598.
6. Borst P: Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012, 2:120066-120066.
7. Touil Y, Igoudjil W, Corvaisier M, Dessein A-F, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot F-R, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G: Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res Off J Am Assoc Cancer Res 2014, 20:837-846.
8. Essers MAG, Trumpp A: Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010, 4:443-450.
9. Tanno T, Matsui W: Development and maintenance of cancer stem cells under chronic inflammation. J Nippon Med Sch 2011, 78:138-145.
10. Kundu JK, Surh Y-J: Emerging avenues linking inflammation and cancer. Free Radic Biol Med 2012, 52:2013-2037.
11. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
12. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002, 13:135-141.
13. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454:436-444.
14. Hruza LL, Pentland AP: Mechanisms of UV-induced inflammation. J Invest Dermatol 1993, 100: 35S-41S.
15. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP: Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
16. Tumbar T: Defining the epithelial stem cell niche in skin. Science 2004, 303:359-363.
17. Kanda T, Sullivan KF, Wahl GM: Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol CB 1998, 8:377-385.
18. Tesio M, Trumpp A: Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell 2011, 9:187-192.
19. Schatton T, Frank NY, Frank MH: Identification and targeting of cancer stem cells. BioEssays 2009, 31:1038-1049.
20. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL: Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
21. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, Waaga-Gasser A-M, Kupper TS, Murphy GF, Frank MH: VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011, 71:1474-1485.
22. Dupin E, Coelho-Aguiar JM: Isolation and differentiation properties of neural crest stem cells. Cytometry A 2013, 83A:38-47.
23. Liu J, Sato C, Cerletti M, Wagers A: Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 2010, 92:367-409. Elsevier.
24. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
25. Croft M, Benedict CA, Ware CF: Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013, 12:147-168.
26. Reynolds BA, Weiss S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710.
27. Perego M, Alison MR, Mariani L, Rivoltini L, Castelli C: Spheres of influence in cancer stem cell biology. J Invest Dermatol 2010, 131:546-547.
28. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010, 148:3-15.
29. Davies MA, Samuels Y: Analysis of the genome to personalize therapy for melanoma. Oncogene 2010, 29:5545-5555.
30. Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L, Meyer N, Gairin JE, Guilbaud N, Annereau JP: Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS ONE 2012, 7:e36762.
31. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
32. Eves P, Layton C, Hedley S, Dawson RA, Wagner M, Morandini R, Ghanem G, Mac Neil S: Characterization of an in vitro model of human melanoma invasion based on reconstructed human skin. Br J Dermatol 2000, 142:210-222.
33. Li L, Fukunaga-Kalabis M, Herlyn M: The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp JoVE 2011, 54:e2937.
34. Touil Y, Zuliani T, Wolowczuk I, Kuranda K, Prochazkova J, Andrieux J, Le Roy H, Mortier L, Vandomme J, Jouy N, Masselot B, Ségard P, Quesnel B, Formstecher P, Polakowska R: The PI3K/AKT signaling pathway controls the quiescence of the Low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. STEM CELLS 2013, 31:641-651.
35. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T: Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012, 490:412-416.
36. Takizawa H, Regoes RR, Boddupalli CS, Bonhoeffer S, Manz MG: Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J Exp Med 2011, 208:273-284.
37. Jiang B, Liu L: Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis. In Adv Cancer Res, Volume 102. Edited by Vande Woude GF, Klein G. Elsevier: 2009:19-65.
38. Kimura T, Nakano T: Regulation of Stem Cell Systems by PI3K/Akt Signaling. In Regul Netw Stem Cells. Edited by Rajasekhar VK, Vemuri MC. New York: Humana Press; 2009:309-318.
39. Ito K, Suda T: Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 2014, 15:243-256.
40. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Gilliland DG, Armstrong SA, Scadden DT: AKT/ FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011, 146:697-708.
41. Wray J, Kalkan T, Gomez-Lopez S, Eckardt D, Cook A, Kemler R, Smith A: Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation. Nat Cell Biol 2011, 13:838-845.
42. Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J Sudbury Mass 2012, 18:142-147.
43. Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA, Libra M: Emerging targeted therapies for melanoma treatment (Review). Int J Oncol 2014, 45:516-524.
44. Richmond A: NF-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2:664-674.
45. Smale ST: Hierarchies of NF-κB target-gene regulation. Nat Immunol 2011, 12:689-694.
46. Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011, 12:715-723.
47. Baldridge MT, King KY, Goodell MA: Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011, 32:57-65.
48. Meng F, Liu L, Chin PC, D'Mello SR: Akt is a downstream target of NF-kappa B. J Biol Chem 2002, 277:29674-29680.
49. Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-κB signaling pathways. Nat Immunol 2011, 12:695-708.
50. Sundaramoorthy S, Ryu MS, Lim IK: B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFκB pathways which enhances transcription of MnSOD by accelerating IκB á degradation in normal and cancer cells. Cell Commun Signal CCS 2013, 11:69-83.
51. Moore N, Lyle S: Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol 2011, 2011. Article PMID 396076,11 pages (doi:10.1155/2011/39606 http://www.hindawi.com/journals/jo/2011/396076/).
52. Cheung TH, Rando TA: Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol 2013, 14:329-340.
53. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz H-J: Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2011, 18: 645-653.
54. Shigdar S, Li Y, Bhattacharya S, O'Connor M, Pu C, Lin J, Wang T, Xiang D, Kong L, Wei MQ, Zhu Y, Zhou S, Duan W: Inflammation and cancer stem cells. Cancer Lett 2014, 345:271-278.
55. Schuettpelz LG, Link DC: Regulation of hematopoietic stem cell activity by inflammation. Front Immunol 2013, 4:204-213.
56. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG: The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
57. Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395.
58. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E: PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014, 46:372-383.
59. Wilson BJ, Saab KR, Ma j, Schatton T, Putz P, Zhan Q, Murphy GF, Gasser M, Waaga-Gasser AM, Frank NY, Frank MH: ABCB5 maintains melanoma-initiating cells through a proinflammatory signaling circuits. Cancer Res 2014, 74:4196-4207.
60. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
61. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA: Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci 2011, 108:7950-7955.
62. Poole A, Knowland N, Cooper E, Cole R, Wang H, Booth L, Kacer D, Tarantini F, Friesel R, Prudovsky I: Transitory FGF treatment results in the long-lasting suppression of the proliferative response to repeated FGF stimulation. J Cell Biochem 2014, 115:874-888.
63. Tang DG: Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472.
64. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H: SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 2010, 10:411-427.
65. Amoyel M, Bach EA: Cell competition: how to eliminate your neighbours. Dev Camb Engl 2014, 141:988-1000.
66. Levayer R, Moreno E: Mechanisms of cell competition: themes and variations. J Cell Biol 2013, 200:689-698.
67. Klein CA: Selection and adaptation during metastatic cancer progression. Nature 2013, 501:365-372.
68. Wang CQF, Akalu YT, Suarez-Farinas M, Gonzalez J, Mitsui H, Lowes MA, Orlow SJ, Manga P, Krueger JG: IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol 2013, 133:2741-2752.
69. Widera D, Mikenberg I, Elvers M, Kaltschmidt C, Kaltschmidt B: Tumor necrosis factor α triggers proliferation of adult neural stem cells via IKK/NF-κB signaling. BMC Neurosci 2006, 7:64-82.
70. Mori T, Sato Y, Miyamoto K, Kobayashi T, Shimizu T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Tando T, Iwasaki R, Kawana H, Morioka H, Matsumoto M, Saya H, Toyama Y, Miyamoto T: TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state. Oncogene 2013, 33:4236-4241.
71. Rusten LS, Jacobsen FW, Lesslauer W, Loetscher H, Smeland EB, Jacobsen SE: Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: involvement of p55 and p75 TNF receptors. Blood 1994, 83:3152-3159.
72. Pronk CJH, Veiby OP, Bryder D, Jacobsen SEW: Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med 2011, 208:1563-1570.
73. Dybedal I: Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001, 98:1782-1791.
74. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
75. Dey-Guha I, Wolfer A, Yeh AC, Albeck JG, Darp R, Leon E, Wulfkuhle J, Petricoin EF, Wittner BS, Ramaswamy S: Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci 2011, 108:12845-12850.
76. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ: Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer J Int Cancer 1988, 41:248-255.
77. Le Roy H, Zuliani T, Wolowczuk I, Faivre N, Jouy N, Masselot B, Kerkaert J-P, Formstecher P, Polakowska R: Asymmetric distribution of epidermal growth factor receptor directs the fate of normal and cancer keratinocytes in vitro. Stem Cells Dev 2010, 19:209-220.
78. Haake AR, Polakowska RR: UV-induced apoptosis in skin equivalents: inhibition by phorbol ester and Bcl-2 overexpression. Cell Death Differ 1995, 2:183-193.